Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers

767
50
Favorite

Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers

seekingalpha2022-01-30

Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

767

Report

Comment（50）

PatWong
·2022-01-31
Sell
Reply
2
Report
Jim LEO
·2022-01-31
[smile]
Reply
3
Report
MHh
·2022-01-31
Those who depended less on vaccine or covid treatment sales might have more predictable sales moving forward?
Reply
10
Report
Targarean
·2022-01-31
Seems like the easier way to gain immunity is to catch the virus and a large % already have in Europe and across the world
Reply
4
Report
丰人
·2022-01-31
Like
Reply
3
Report
R Lim
·2022-01-31
Ok
Reply
3
Report
Noob6
·2022-01-31
Ok
Reply
5
Report
HF133
·2022-01-31
Ok
Reply
4
Report
Doris11
·2022-01-31
Like please
Reply
3
Report
Alex1709
·2022-01-31
Good analysis
Reply
6
Report
newwen
·2022-01-31
Up
Reply
9
Report
Sunny0809
·2022-01-31
Ok
Reply
5
Report
Alkid
·2022-01-31
Ok
Reply
5
Report
老木不朽
·2022-01-31
K
Reply
5
Report
ML808
·2022-01-31
Great
Reply
7
Report
Simplewind
·2022-01-31
Pls like. Thanks
Reply
5
Report
whyskysoshy
·2022-01-31
🤙
Reply
4
Report
Zero_onezero
·2022-01-31
Ok
Reply
4
Report
JoshuaLiew
·2022-01-31
Ok
Reply
3
Report
TradeLegend
·2022-01-31
🤑
Reply
5
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2207441801?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-01-30 11:40","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2207441801","market":"us","top_or_hot":-1,"title":"Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers","media":"seekingalpha","content":"<div>\n<p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JNJ","symbol_name":"强生","start_time":0,"source_url":"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers","article_id":"2207441801","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2207441801","pubTimestamp":1643514032,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with weal","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"JNJ":"强生","NVS":"诺华","BK4551":"寇图资本持仓","LLY":"礼来","BK4504":"桥水持仓","SNY":"赛诺菲安万特","BK4548":"巴美列捷福持仓","MRNA":"Moderna, Inc.","BMY":"施贵宝","PFE":"辉瑞","BK4516":"特朗普概念","ABBV":"艾伯维公司","GILD":"吉利德科学","BK4532":"文艺复兴科技持仓","BNTX":"BioNTech SE","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","REGN":"再生元制药公司","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRK":"默沙东","BK4568":"美国抗疫概念"},"translate_title":"疫苗将主导今年的制药销售，但布里斯托尔可能会有最畅销的","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":1,"REGN":1,"PFE":1,"NVS":1,"MRNA":1,"MRK":1,"LLY":1,"JNJ":1,"GILD":1,"BNTX":1,"BMY":1,"ABBV":1},"content_text":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.Financial analytics firm Evaluate Vantage projects that Pfizer /BioNTech's  COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.Coming in at No. 2 on the list with predicted sales of ~$20B is AbbVie's  TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.Two products are tied for No. 3. The first is Moderna's  COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.Also in third place with $19.5B in projected sales is Merck's  PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.Two Bristol-Myers Squibb  drugs come in the fifth and sixth spots. They are Eliquis  at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.Coming in at Nos. 7, 8, and 10 respectively are Johnson & Johnson's (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); Gilead Sciences'  Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and Sanofi/Regeneron PharmaceuticalsDupixent (dupilimuab) (~$7.5B).The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson & Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&J at around ~$54B.In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer's disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&J.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9093891390,"gmtCreate":1643586416825,"gmtModify":1676533832677,"author":{"id":"4092487035590380","authorId":"4092487035590380","name":"PatWong","avatar":"https://static.tigerbbs.com/6d2db4fdb2321496faf7af320ac6557d","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Sell","listText":"Sell","text":"Sell","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093891390","repostId":2207441801,"repostType":4,"repost":{"id":"2207441801","pubTimestamp":1643514032,"share":"https://www.laohu8.com/m/news/2207441801?lang=&edition=full","pubTime":"2022-01-30 11:40","market":"us","language":"en","title":"Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers","url":"https://stock-news.laohu8.com/highlight/detail?id=2207441801","media":"seekingalpha","summary":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with weal","content":"<html><head></head><body><p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn&#39;t come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.</p><p>Financial analytics firm Evaluate Vantage projects that <a href=\"https://laohu8.com/S/PFE\">Pfizer </a>/<a href=\"https://laohu8.com/S/BNTX\">BioNTech&#39;s </a> COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.</p><p>Coming in at No. 2 on the list with predicted sales of ~$20B is <a href=\"https://laohu8.com/S/ABBV\">AbbVie&#39;s </a> TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.</p><p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> products are tied for No. 3. The first is <a href=\"https://laohu8.com/S/MRNA\">Moderna&#39;s </a> COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.</p><p>Also in third place with $19.5B in projected sales is <a href=\"https://laohu8.com/S/MRK\">Merck&#39;s </a> PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_Vantage2022drugsales_thumb1.png\" tg-width=\"1172\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Two <a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb </a> drugs come in the fifth and sixth spots. They are <a href=\"https://laohu8.com/S/apixaban\">Eliquis </a> at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.</p><p>A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.</p><p>Coming in at Nos. 7, 8, and 10 respectively are Johnson &amp; Johnson&#39;s (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences&#39; </a> Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>/<a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a>Dupixent (dupilimuab) (~$7.5B).</p><p>The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson &amp; Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_VantageRxsales_thumb1.png\" tg-width=\"1162\" tg-height=\"614\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&amp;J at around ~$54B.</p><p>In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer&#39;s disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.</p><p>While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&amp;J.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","NVS":"诺华","BK4551":"寇图资本持仓","LLY":"礼来","BK4504":"桥水持仓","SNY":"赛诺菲安万特","BK4548":"巴美列捷福持仓","MRNA":"Moderna, Inc.","BMY":"施贵宝","PFE":"辉瑞","BK4516":"特朗普概念","ABBV":"艾伯维公司","GILD":"吉利德科学","BK4532":"文艺复兴科技持仓","BNTX":"BioNTech SE","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","REGN":"再生元制药公司","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRK":"默沙东","BK4568":"美国抗疫概念"},"source_url":"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207441801","content_text":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.Financial analytics firm Evaluate Vantage projects that Pfizer /BioNTech's  COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.Coming in at No. 2 on the list with predicted sales of ~$20B is AbbVie's  TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.Two products are tied for No. 3. The first is Moderna's  COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.Also in third place with $19.5B in projected sales is Merck's  PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.Two Bristol-Myers Squibb  drugs come in the fifth and sixth spots. They are Eliquis  at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.Coming in at Nos. 7, 8, and 10 respectively are Johnson & Johnson's (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); Gilead Sciences'  Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and Sanofi/Regeneron PharmaceuticalsDupixent (dupilimuab) (~$7.5B).The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson & Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&J at around ~$54B.In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer's disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&J.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093805856,"gmtCreate":1643585567798,"gmtModify":1676533832566,"author":{"id":"4103490940855160","authorId":"4103490940855160","name":"Jim LEO","avatar":"https://static.itradeup.com/news/0319adfc256ed9b9969f115e5adc7840","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"[smile]&nbsp;","listText":"[smile]&nbsp;","text":"[smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093805856","repostId":2207441801,"repostType":2,"repost":{"id":"2207441801","pubTimestamp":1643514032,"share":"https://www.laohu8.com/m/news/2207441801?lang=&edition=full","pubTime":"2022-01-30 11:40","market":"us","language":"en","title":"Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers","url":"https://stock-news.laohu8.com/highlight/detail?id=2207441801","media":"seekingalpha","summary":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with weal","content":"<html><head></head><body><p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn&#39;t come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.</p><p>Financial analytics firm Evaluate Vantage projects that <a href=\"https://laohu8.com/S/PFE\">Pfizer </a>/<a href=\"https://laohu8.com/S/BNTX\">BioNTech&#39;s </a> COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.</p><p>Coming in at No. 2 on the list with predicted sales of ~$20B is <a href=\"https://laohu8.com/S/ABBV\">AbbVie&#39;s </a> TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.</p><p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> products are tied for No. 3. The first is <a href=\"https://laohu8.com/S/MRNA\">Moderna&#39;s </a> COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.</p><p>Also in third place with $19.5B in projected sales is <a href=\"https://laohu8.com/S/MRK\">Merck&#39;s </a> PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_Vantage2022drugsales_thumb1.png\" tg-width=\"1172\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Two <a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb </a> drugs come in the fifth and sixth spots. They are <a href=\"https://laohu8.com/S/apixaban\">Eliquis </a> at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.</p><p>A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.</p><p>Coming in at Nos. 7, 8, and 10 respectively are Johnson &amp; Johnson&#39;s (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences&#39; </a> Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>/<a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a>Dupixent (dupilimuab) (~$7.5B).</p><p>The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson &amp; Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_VantageRxsales_thumb1.png\" tg-width=\"1162\" tg-height=\"614\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&amp;J at around ~$54B.</p><p>In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer&#39;s disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.</p><p>While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&amp;J.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","NVS":"诺华","BK4551":"寇图资本持仓","LLY":"礼来","BK4504":"桥水持仓","SNY":"赛诺菲安万特","BK4548":"巴美列捷福持仓","MRNA":"Moderna, Inc.","BMY":"施贵宝","PFE":"辉瑞","BK4516":"特朗普概念","ABBV":"艾伯维公司","GILD":"吉利德科学","BK4532":"文艺复兴科技持仓","BNTX":"BioNTech SE","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","REGN":"再生元制药公司","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRK":"默沙东","BK4568":"美国抗疫概念"},"source_url":"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207441801","content_text":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.Financial analytics firm Evaluate Vantage projects that Pfizer /BioNTech's  COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.Coming in at No. 2 on the list with predicted sales of ~$20B is AbbVie's  TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.Two products are tied for No. 3. The first is Moderna's  COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.Also in third place with $19.5B in projected sales is Merck's  PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.Two Bristol-Myers Squibb  drugs come in the fifth and sixth spots. They are Eliquis  at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.Coming in at Nos. 7, 8, and 10 respectively are Johnson & Johnson's (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); Gilead Sciences'  Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and Sanofi/Regeneron PharmaceuticalsDupixent (dupilimuab) (~$7.5B).The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson & Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&J at around ~$54B.In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer's disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&J.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093801820,"gmtCreate":1643585082103,"gmtModify":1676533832472,"author":{"id":"4091758936365950","authorId":"4091758936365950","name":"MHh","avatar":"https://static.tigerbbs.com/54b2feced9ef5dcc9e95997d1f4db280","vip":1,"crmLevel":6,"crmLevelSwitch":1},"htmlText":"Those who depended less on vaccine or covid treatment sales might have more predictable sales moving forward?","listText":"Those who depended less on vaccine or covid treatment sales might have more predictable sales moving forward?","text":"Those who depended less on vaccine or covid treatment sales might have more predictable sales moving forward?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093801820","repostId":2207441801,"repostType":4,"repost":{"id":"2207441801","pubTimestamp":1643514032,"share":"https://www.laohu8.com/m/news/2207441801?lang=&edition=full","pubTime":"2022-01-30 11:40","market":"us","language":"en","title":"Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers","url":"https://stock-news.laohu8.com/highlight/detail?id=2207441801","media":"seekingalpha","summary":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with weal","content":"<html><head></head><body><p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn&#39;t come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.</p><p>Financial analytics firm Evaluate Vantage projects that <a href=\"https://laohu8.com/S/PFE\">Pfizer </a>/<a href=\"https://laohu8.com/S/BNTX\">BioNTech&#39;s </a> COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.</p><p>Coming in at No. 2 on the list with predicted sales of ~$20B is <a href=\"https://laohu8.com/S/ABBV\">AbbVie&#39;s </a> TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.</p><p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> products are tied for No. 3. The first is <a href=\"https://laohu8.com/S/MRNA\">Moderna&#39;s </a> COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.</p><p>Also in third place with $19.5B in projected sales is <a href=\"https://laohu8.com/S/MRK\">Merck&#39;s </a> PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_Vantage2022drugsales_thumb1.png\" tg-width=\"1172\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Two <a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb </a> drugs come in the fifth and sixth spots. They are <a href=\"https://laohu8.com/S/apixaban\">Eliquis </a> at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.</p><p>A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.</p><p>Coming in at Nos. 7, 8, and 10 respectively are Johnson &amp; Johnson&#39;s (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences&#39; </a> Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>/<a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a>Dupixent (dupilimuab) (~$7.5B).</p><p>The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson &amp; Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_VantageRxsales_thumb1.png\" tg-width=\"1162\" tg-height=\"614\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&amp;J at around ~$54B.</p><p>In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer&#39;s disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.</p><p>While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&amp;J.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","NVS":"诺华","BK4551":"寇图资本持仓","LLY":"礼来","BK4504":"桥水持仓","SNY":"赛诺菲安万特","BK4548":"巴美列捷福持仓","MRNA":"Moderna, Inc.","BMY":"施贵宝","PFE":"辉瑞","BK4516":"特朗普概念","ABBV":"艾伯维公司","GILD":"吉利德科学","BK4532":"文艺复兴科技持仓","BNTX":"BioNTech SE","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","REGN":"再生元制药公司","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRK":"默沙东","BK4568":"美国抗疫概念"},"source_url":"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207441801","content_text":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.Financial analytics firm Evaluate Vantage projects that Pfizer /BioNTech's  COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.Coming in at No. 2 on the list with predicted sales of ~$20B is AbbVie's  TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.Two products are tied for No. 3. The first is Moderna's  COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.Also in third place with $19.5B in projected sales is Merck's  PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.Two Bristol-Myers Squibb  drugs come in the fifth and sixth spots. They are Eliquis  at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.Coming in at Nos. 7, 8, and 10 respectively are Johnson & Johnson's (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); Gilead Sciences'  Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and Sanofi/Regeneron PharmaceuticalsDupixent (dupilimuab) (~$7.5B).The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson & Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&J at around ~$54B.In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer's disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&J.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093809888,"gmtCreate":1643584830715,"gmtModify":1676533832403,"author":{"id":"3573540190522229","authorId":"3573540190522229","name":"Targarean","avatar":"https://community-static.tradeup.com/news/59de1c73df3e7e460bd84cc786850fa6","vip":1,"hat":"https://static.tigerbbs.com/ae1f49570794979e009a5efdeb6f4789","crmLevel":7,"crmLevelSwitch":1},"htmlText":"Seems like the easier way to gain immunity is to catch the virus and a large % already have in Europe and across the world&nbsp;","listText":"Seems like the easier way to gain immunity is to catch the virus and a large % already have in Europe and across the world&nbsp;","text":"Seems like the easier way to gain immunity is to catch the virus and a large % already have in Europe and across the world","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093809888","repostId":2207441801,"repostType":4,"repost":{"id":"2207441801","pubTimestamp":1643514032,"share":"https://www.laohu8.com/m/news/2207441801?lang=&edition=full","pubTime":"2022-01-30 11:40","market":"us","language":"en","title":"Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers","url":"https://stock-news.laohu8.com/highlight/detail?id=2207441801","media":"seekingalpha","summary":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with weal","content":"<html><head></head><body><p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn&#39;t come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.</p><p>Financial analytics firm Evaluate Vantage projects that <a href=\"https://laohu8.com/S/PFE\">Pfizer </a>/<a href=\"https://laohu8.com/S/BNTX\">BioNTech&#39;s </a> COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.</p><p>Coming in at No. 2 on the list with predicted sales of ~$20B is <a href=\"https://laohu8.com/S/ABBV\">AbbVie&#39;s </a> TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.</p><p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> products are tied for No. 3. The first is <a href=\"https://laohu8.com/S/MRNA\">Moderna&#39;s </a> COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.</p><p>Also in third place with $19.5B in projected sales is <a href=\"https://laohu8.com/S/MRK\">Merck&#39;s </a> PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_Vantage2022drugsales_thumb1.png\" tg-width=\"1172\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Two <a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb </a> drugs come in the fifth and sixth spots. They are <a href=\"https://laohu8.com/S/apixaban\">Eliquis </a> at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.</p><p>A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.</p><p>Coming in at Nos. 7, 8, and 10 respectively are Johnson &amp; Johnson&#39;s (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences&#39; </a> Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>/<a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a>Dupixent (dupilimuab) (~$7.5B).</p><p>The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson &amp; Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_VantageRxsales_thumb1.png\" tg-width=\"1162\" tg-height=\"614\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&amp;J at around ~$54B.</p><p>In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer&#39;s disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.</p><p>While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&amp;J.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","NVS":"诺华","BK4551":"寇图资本持仓","LLY":"礼来","BK4504":"桥水持仓","SNY":"赛诺菲安万特","BK4548":"巴美列捷福持仓","MRNA":"Moderna, Inc.","BMY":"施贵宝","PFE":"辉瑞","BK4516":"特朗普概念","ABBV":"艾伯维公司","GILD":"吉利德科学","BK4532":"文艺复兴科技持仓","BNTX":"BioNTech SE","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","REGN":"再生元制药公司","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRK":"默沙东","BK4568":"美国抗疫概念"},"source_url":"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207441801","content_text":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.Financial analytics firm Evaluate Vantage projects that Pfizer /BioNTech's  COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.Coming in at No. 2 on the list with predicted sales of ~$20B is AbbVie's  TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.Two products are tied for No. 3. The first is Moderna's  COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.Also in third place with $19.5B in projected sales is Merck's  PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.Two Bristol-Myers Squibb  drugs come in the fifth and sixth spots. They are Eliquis  at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.Coming in at Nos. 7, 8, and 10 respectively are Johnson & Johnson's (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); Gilead Sciences'  Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and Sanofi/Regeneron PharmaceuticalsDupixent (dupilimuab) (~$7.5B).The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson & Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&J at around ~$54B.In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer's disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&J.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093176570,"gmtCreate":1643583944775,"gmtModify":1676533832256,"author":{"id":"4088035849823630","authorId":"4088035849823630","name":"丰人","avatar":"https://static.tigerbbs.com/35bfaa2970044533bc9763d63a71e1dd","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093176570","repostId":2207441801,"repostType":4,"repost":{"id":"2207441801","pubTimestamp":1643514032,"share":"https://www.laohu8.com/m/news/2207441801?lang=&edition=full","pubTime":"2022-01-30 11:40","market":"us","language":"en","title":"Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers","url":"https://stock-news.laohu8.com/highlight/detail?id=2207441801","media":"seekingalpha","summary":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with weal","content":"<html><head></head><body><p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn&#39;t come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.</p><p>Financial analytics firm Evaluate Vantage projects that <a href=\"https://laohu8.com/S/PFE\">Pfizer </a>/<a href=\"https://laohu8.com/S/BNTX\">BioNTech&#39;s </a> COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.</p><p>Coming in at No. 2 on the list with predicted sales of ~$20B is <a href=\"https://laohu8.com/S/ABBV\">AbbVie&#39;s </a> TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.</p><p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> products are tied for No. 3. The first is <a href=\"https://laohu8.com/S/MRNA\">Moderna&#39;s </a> COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.</p><p>Also in third place with $19.5B in projected sales is <a href=\"https://laohu8.com/S/MRK\">Merck&#39;s </a> PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_Vantage2022drugsales_thumb1.png\" tg-width=\"1172\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Two <a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb </a> drugs come in the fifth and sixth spots. They are <a href=\"https://laohu8.com/S/apixaban\">Eliquis </a> at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.</p><p>A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.</p><p>Coming in at Nos. 7, 8, and 10 respectively are Johnson &amp; Johnson&#39;s (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences&#39; </a> Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>/<a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a>Dupixent (dupilimuab) (~$7.5B).</p><p>The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson &amp; Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_VantageRxsales_thumb1.png\" tg-width=\"1162\" tg-height=\"614\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&amp;J at around ~$54B.</p><p>In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer&#39;s disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.</p><p>While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&amp;J.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","NVS":"诺华","BK4551":"寇图资本持仓","LLY":"礼来","BK4504":"桥水持仓","SNY":"赛诺菲安万特","BK4548":"巴美列捷福持仓","MRNA":"Moderna, Inc.","BMY":"施贵宝","PFE":"辉瑞","BK4516":"特朗普概念","ABBV":"艾伯维公司","GILD":"吉利德科学","BK4532":"文艺复兴科技持仓","BNTX":"BioNTech SE","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","REGN":"再生元制药公司","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRK":"默沙东","BK4568":"美国抗疫概念"},"source_url":"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207441801","content_text":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.Financial analytics firm Evaluate Vantage projects that Pfizer /BioNTech's  COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.Coming in at No. 2 on the list with predicted sales of ~$20B is AbbVie's  TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.Two products are tied for No. 3. The first is Moderna's  COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.Also in third place with $19.5B in projected sales is Merck's  PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.Two Bristol-Myers Squibb  drugs come in the fifth and sixth spots. They are Eliquis  at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.Coming in at Nos. 7, 8, and 10 respectively are Johnson & Johnson's (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); Gilead Sciences'  Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and Sanofi/Regeneron PharmaceuticalsDupixent (dupilimuab) (~$7.5B).The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson & Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&J at around ~$54B.In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer's disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&J.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093171354,"gmtCreate":1643583373569,"gmtModify":1676533832211,"author":{"id":"3581634125853828","authorId":"3581634125853828","name":"R Lim","avatar":"https://static.tigerbbs.com/d3081d4d67e2198188bc8039305c484f","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093171354","repostId":2207441801,"repostType":4,"repost":{"id":"2207441801","pubTimestamp":1643514032,"share":"https://www.laohu8.com/m/news/2207441801?lang=&edition=full","pubTime":"2022-01-30 11:40","market":"us","language":"en","title":"Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers","url":"https://stock-news.laohu8.com/highlight/detail?id=2207441801","media":"seekingalpha","summary":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with weal","content":"<html><head></head><body><p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn&#39;t come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.</p><p>Financial analytics firm Evaluate Vantage projects that <a href=\"https://laohu8.com/S/PFE\">Pfizer </a>/<a href=\"https://laohu8.com/S/BNTX\">BioNTech&#39;s </a> COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.</p><p>Coming in at No. 2 on the list with predicted sales of ~$20B is <a href=\"https://laohu8.com/S/ABBV\">AbbVie&#39;s </a> TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.</p><p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> products are tied for No. 3. The first is <a href=\"https://laohu8.com/S/MRNA\">Moderna&#39;s </a> COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.</p><p>Also in third place with $19.5B in projected sales is <a href=\"https://laohu8.com/S/MRK\">Merck&#39;s </a> PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_Vantage2022drugsales_thumb1.png\" tg-width=\"1172\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Two <a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb </a> drugs come in the fifth and sixth spots. They are <a href=\"https://laohu8.com/S/apixaban\">Eliquis </a> at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.</p><p>A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.</p><p>Coming in at Nos. 7, 8, and 10 respectively are Johnson &amp; Johnson&#39;s (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences&#39; </a> Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>/<a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a>Dupixent (dupilimuab) (~$7.5B).</p><p>The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson &amp; Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_VantageRxsales_thumb1.png\" tg-width=\"1162\" tg-height=\"614\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&amp;J at around ~$54B.</p><p>In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer&#39;s disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.</p><p>While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&amp;J.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","NVS":"诺华","BK4551":"寇图资本持仓","LLY":"礼来","BK4504":"桥水持仓","SNY":"赛诺菲安万特","BK4548":"巴美列捷福持仓","MRNA":"Moderna, Inc.","BMY":"施贵宝","PFE":"辉瑞","BK4516":"特朗普概念","ABBV":"艾伯维公司","GILD":"吉利德科学","BK4532":"文艺复兴科技持仓","BNTX":"BioNTech SE","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","REGN":"再生元制药公司","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRK":"默沙东","BK4568":"美国抗疫概念"},"source_url":"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207441801","content_text":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.Financial analytics firm Evaluate Vantage projects that Pfizer /BioNTech's  COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.Coming in at No. 2 on the list with predicted sales of ~$20B is AbbVie's  TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.Two products are tied for No. 3. The first is Moderna's  COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.Also in third place with $19.5B in projected sales is Merck's  PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.Two Bristol-Myers Squibb  drugs come in the fifth and sixth spots. They are Eliquis  at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.Coming in at Nos. 7, 8, and 10 respectively are Johnson & Johnson's (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); Gilead Sciences'  Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and Sanofi/Regeneron PharmaceuticalsDupixent (dupilimuab) (~$7.5B).The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson & Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&J at around ~$54B.In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer's disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&J.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093173451,"gmtCreate":1643583275222,"gmtModify":1676533832179,"author":{"id":"3577433295437037","authorId":"3577433295437037","name":"Noob6","avatar":"https://static.tigerbbs.com/395476a9381e76bd4cd6eb8b78eddc5e","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093173451","repostId":2207441801,"repostType":4,"repost":{"id":"2207441801","pubTimestamp":1643514032,"share":"https://www.laohu8.com/m/news/2207441801?lang=&edition=full","pubTime":"2022-01-30 11:40","market":"us","language":"en","title":"Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers","url":"https://stock-news.laohu8.com/highlight/detail?id=2207441801","media":"seekingalpha","summary":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with weal","content":"<html><head></head><body><p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn&#39;t come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.</p><p>Financial analytics firm Evaluate Vantage projects that <a href=\"https://laohu8.com/S/PFE\">Pfizer </a>/<a href=\"https://laohu8.com/S/BNTX\">BioNTech&#39;s </a> COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.</p><p>Coming in at No. 2 on the list with predicted sales of ~$20B is <a href=\"https://laohu8.com/S/ABBV\">AbbVie&#39;s </a> TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.</p><p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> products are tied for No. 3. The first is <a href=\"https://laohu8.com/S/MRNA\">Moderna&#39;s </a> COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.</p><p>Also in third place with $19.5B in projected sales is <a href=\"https://laohu8.com/S/MRK\">Merck&#39;s </a> PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_Vantage2022drugsales_thumb1.png\" tg-width=\"1172\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Two <a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb </a> drugs come in the fifth and sixth spots. They are <a href=\"https://laohu8.com/S/apixaban\">Eliquis </a> at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.</p><p>A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.</p><p>Coming in at Nos. 7, 8, and 10 respectively are Johnson &amp; Johnson&#39;s (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences&#39; </a> Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>/<a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a>Dupixent (dupilimuab) (~$7.5B).</p><p>The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson &amp; Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_VantageRxsales_thumb1.png\" tg-width=\"1162\" tg-height=\"614\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&amp;J at around ~$54B.</p><p>In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer&#39;s disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.</p><p>While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&amp;J.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","NVS":"诺华","BK4551":"寇图资本持仓","LLY":"礼来","BK4504":"桥水持仓","SNY":"赛诺菲安万特","BK4548":"巴美列捷福持仓","MRNA":"Moderna, Inc.","BMY":"施贵宝","PFE":"辉瑞","BK4516":"特朗普概念","ABBV":"艾伯维公司","GILD":"吉利德科学","BK4532":"文艺复兴科技持仓","BNTX":"BioNTech SE","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","REGN":"再生元制药公司","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRK":"默沙东","BK4568":"美国抗疫概念"},"source_url":"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207441801","content_text":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.Financial analytics firm Evaluate Vantage projects that Pfizer /BioNTech's  COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.Coming in at No. 2 on the list with predicted sales of ~$20B is AbbVie's  TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.Two products are tied for No. 3. The first is Moderna's  COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.Also in third place with $19.5B in projected sales is Merck's  PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.Two Bristol-Myers Squibb  drugs come in the fifth and sixth spots. They are Eliquis  at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.Coming in at Nos. 7, 8, and 10 respectively are Johnson & Johnson's (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); Gilead Sciences'  Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and Sanofi/Regeneron PharmaceuticalsDupixent (dupilimuab) (~$7.5B).The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson & Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&J at around ~$54B.In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer's disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&J.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093144584,"gmtCreate":1643582372997,"gmtModify":1676533832063,"author":{"id":"3583621807888930","authorId":"3583621807888930","name":"HF133","avatar":"https://static.tigerbbs.com/ce211305e06a021e08ecfcbc0e23bbb5","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093144584","repostId":2207441801,"repostType":4,"repost":{"id":"2207441801","pubTimestamp":1643514032,"share":"https://www.laohu8.com/m/news/2207441801?lang=&edition=full","pubTime":"2022-01-30 11:40","market":"us","language":"en","title":"Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers","url":"https://stock-news.laohu8.com/highlight/detail?id=2207441801","media":"seekingalpha","summary":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with weal","content":"<html><head></head><body><p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn&#39;t come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.</p><p>Financial analytics firm Evaluate Vantage projects that <a href=\"https://laohu8.com/S/PFE\">Pfizer </a>/<a href=\"https://laohu8.com/S/BNTX\">BioNTech&#39;s </a> COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.</p><p>Coming in at No. 2 on the list with predicted sales of ~$20B is <a href=\"https://laohu8.com/S/ABBV\">AbbVie&#39;s </a> TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.</p><p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> products are tied for No. 3. The first is <a href=\"https://laohu8.com/S/MRNA\">Moderna&#39;s </a> COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.</p><p>Also in third place with $19.5B in projected sales is <a href=\"https://laohu8.com/S/MRK\">Merck&#39;s </a> PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_Vantage2022drugsales_thumb1.png\" tg-width=\"1172\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Two <a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb </a> drugs come in the fifth and sixth spots. They are <a href=\"https://laohu8.com/S/apixaban\">Eliquis </a> at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.</p><p>A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.</p><p>Coming in at Nos. 7, 8, and 10 respectively are Johnson &amp; Johnson&#39;s (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences&#39; </a> Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>/<a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a>Dupixent (dupilimuab) (~$7.5B).</p><p>The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson &amp; Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_VantageRxsales_thumb1.png\" tg-width=\"1162\" tg-height=\"614\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&amp;J at around ~$54B.</p><p>In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer&#39;s disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.</p><p>While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&amp;J.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","NVS":"诺华","BK4551":"寇图资本持仓","LLY":"礼来","BK4504":"桥水持仓","SNY":"赛诺菲安万特","BK4548":"巴美列捷福持仓","MRNA":"Moderna, Inc.","BMY":"施贵宝","PFE":"辉瑞","BK4516":"特朗普概念","ABBV":"艾伯维公司","GILD":"吉利德科学","BK4532":"文艺复兴科技持仓","BNTX":"BioNTech SE","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","REGN":"再生元制药公司","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRK":"默沙东","BK4568":"美国抗疫概念"},"source_url":"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207441801","content_text":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.Financial analytics firm Evaluate Vantage projects that Pfizer /BioNTech's  COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.Coming in at No. 2 on the list with predicted sales of ~$20B is AbbVie's  TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.Two products are tied for No. 3. The first is Moderna's  COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.Also in third place with $19.5B in projected sales is Merck's  PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.Two Bristol-Myers Squibb  drugs come in the fifth and sixth spots. They are Eliquis  at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.Coming in at Nos. 7, 8, and 10 respectively are Johnson & Johnson's (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); Gilead Sciences'  Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and Sanofi/Regeneron PharmaceuticalsDupixent (dupilimuab) (~$7.5B).The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson & Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&J at around ~$54B.In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer's disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&J.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093144238,"gmtCreate":1643582363721,"gmtModify":1676533832063,"author":{"id":"3583011761877766","authorId":"3583011761877766","name":"Doris11","avatar":"https://static.tigerbbs.com/3358aeedff213df7d1787b8f5e7a99ec","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093144238","repostId":2207441801,"repostType":4,"repost":{"id":"2207441801","pubTimestamp":1643514032,"share":"https://www.laohu8.com/m/news/2207441801?lang=&edition=full","pubTime":"2022-01-30 11:40","market":"us","language":"en","title":"Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers","url":"https://stock-news.laohu8.com/highlight/detail?id=2207441801","media":"seekingalpha","summary":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with weal","content":"<html><head></head><body><p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn&#39;t come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.</p><p>Financial analytics firm Evaluate Vantage projects that <a href=\"https://laohu8.com/S/PFE\">Pfizer </a>/<a href=\"https://laohu8.com/S/BNTX\">BioNTech&#39;s </a> COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.</p><p>Coming in at No. 2 on the list with predicted sales of ~$20B is <a href=\"https://laohu8.com/S/ABBV\">AbbVie&#39;s </a> TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.</p><p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> products are tied for No. 3. The first is <a href=\"https://laohu8.com/S/MRNA\">Moderna&#39;s </a> COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.</p><p>Also in third place with $19.5B in projected sales is <a href=\"https://laohu8.com/S/MRK\">Merck&#39;s </a> PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_Vantage2022drugsales_thumb1.png\" tg-width=\"1172\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Two <a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb </a> drugs come in the fifth and sixth spots. They are <a href=\"https://laohu8.com/S/apixaban\">Eliquis </a> at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.</p><p>A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.</p><p>Coming in at Nos. 7, 8, and 10 respectively are Johnson &amp; Johnson&#39;s (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences&#39; </a> Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>/<a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a>Dupixent (dupilimuab) (~$7.5B).</p><p>The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson &amp; Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_VantageRxsales_thumb1.png\" tg-width=\"1162\" tg-height=\"614\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&amp;J at around ~$54B.</p><p>In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer&#39;s disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.</p><p>While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&amp;J.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","NVS":"诺华","BK4551":"寇图资本持仓","LLY":"礼来","BK4504":"桥水持仓","SNY":"赛诺菲安万特","BK4548":"巴美列捷福持仓","MRNA":"Moderna, Inc.","BMY":"施贵宝","PFE":"辉瑞","BK4516":"特朗普概念","ABBV":"艾伯维公司","GILD":"吉利德科学","BK4532":"文艺复兴科技持仓","BNTX":"BioNTech SE","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","REGN":"再生元制药公司","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRK":"默沙东","BK4568":"美国抗疫概念"},"source_url":"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207441801","content_text":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.Financial analytics firm Evaluate Vantage projects that Pfizer /BioNTech's  COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.Coming in at No. 2 on the list with predicted sales of ~$20B is AbbVie's  TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.Two products are tied for No. 3. The first is Moderna's  COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.Also in third place with $19.5B in projected sales is Merck's  PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.Two Bristol-Myers Squibb  drugs come in the fifth and sixth spots. They are Eliquis  at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.Coming in at Nos. 7, 8, and 10 respectively are Johnson & Johnson's (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); Gilead Sciences'  Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and Sanofi/Regeneron PharmaceuticalsDupixent (dupilimuab) (~$7.5B).The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson & Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&J at around ~$54B.In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer's disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&J.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093148766,"gmtCreate":1643581606372,"gmtModify":1676533831865,"author":{"id":"4088812812352770","authorId":"4088812812352770","name":"Alex1709","avatar":"https://static.tigerbbs.com/b4371c8d3e464d94c77cc0d40b9d3f48","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"Good analysis","listText":"Good analysis","text":"Good analysis","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093148766","repostId":2207441801,"repostType":4,"repost":{"id":"2207441801","pubTimestamp":1643514032,"share":"https://www.laohu8.com/m/news/2207441801?lang=&edition=full","pubTime":"2022-01-30 11:40","market":"us","language":"en","title":"Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers","url":"https://stock-news.laohu8.com/highlight/detail?id=2207441801","media":"seekingalpha","summary":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with weal","content":"<html><head></head><body><p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn&#39;t come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.</p><p>Financial analytics firm Evaluate Vantage projects that <a href=\"https://laohu8.com/S/PFE\">Pfizer </a>/<a href=\"https://laohu8.com/S/BNTX\">BioNTech&#39;s </a> COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.</p><p>Coming in at No. 2 on the list with predicted sales of ~$20B is <a href=\"https://laohu8.com/S/ABBV\">AbbVie&#39;s </a> TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.</p><p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> products are tied for No. 3. The first is <a href=\"https://laohu8.com/S/MRNA\">Moderna&#39;s </a> COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.</p><p>Also in third place with $19.5B in projected sales is <a href=\"https://laohu8.com/S/MRK\">Merck&#39;s </a> PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_Vantage2022drugsales_thumb1.png\" tg-width=\"1172\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Two <a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb </a> drugs come in the fifth and sixth spots. They are <a href=\"https://laohu8.com/S/apixaban\">Eliquis </a> at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.</p><p>A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.</p><p>Coming in at Nos. 7, 8, and 10 respectively are Johnson &amp; Johnson&#39;s (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences&#39; </a> Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>/<a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a>Dupixent (dupilimuab) (~$7.5B).</p><p>The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson &amp; Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_VantageRxsales_thumb1.png\" tg-width=\"1162\" tg-height=\"614\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&amp;J at around ~$54B.</p><p>In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer&#39;s disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.</p><p>While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&amp;J.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","NVS":"诺华","BK4551":"寇图资本持仓","LLY":"礼来","BK4504":"桥水持仓","SNY":"赛诺菲安万特","BK4548":"巴美列捷福持仓","MRNA":"Moderna, Inc.","BMY":"施贵宝","PFE":"辉瑞","BK4516":"特朗普概念","ABBV":"艾伯维公司","GILD":"吉利德科学","BK4532":"文艺复兴科技持仓","BNTX":"BioNTech SE","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","REGN":"再生元制药公司","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRK":"默沙东","BK4568":"美国抗疫概念"},"source_url":"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207441801","content_text":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.Financial analytics firm Evaluate Vantage projects that Pfizer /BioNTech's  COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.Coming in at No. 2 on the list with predicted sales of ~$20B is AbbVie's  TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.Two products are tied for No. 3. The first is Moderna's  COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.Also in third place with $19.5B in projected sales is Merck's  PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.Two Bristol-Myers Squibb  drugs come in the fifth and sixth spots. They are Eliquis  at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.Coming in at Nos. 7, 8, and 10 respectively are Johnson & Johnson's (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); Gilead Sciences'  Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and Sanofi/Regeneron PharmaceuticalsDupixent (dupilimuab) (~$7.5B).The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson & Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&J at around ~$54B.In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer's disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&J.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093157888,"gmtCreate":1643580376399,"gmtModify":1676533831718,"author":{"id":"3577937302028167","authorId":"3577937302028167","name":"newwen","avatar":"https://community-static.tradeup.com/news/d76e150284d102a1d312d08f6f90af41","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Up","listText":"Up","text":"Up","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093157888","repostId":2207441801,"repostType":4,"repost":{"id":"2207441801","pubTimestamp":1643514032,"share":"https://www.laohu8.com/m/news/2207441801?lang=&edition=full","pubTime":"2022-01-30 11:40","market":"us","language":"en","title":"Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers","url":"https://stock-news.laohu8.com/highlight/detail?id=2207441801","media":"seekingalpha","summary":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with weal","content":"<html><head></head><body><p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn&#39;t come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.</p><p>Financial analytics firm Evaluate Vantage projects that <a href=\"https://laohu8.com/S/PFE\">Pfizer </a>/<a href=\"https://laohu8.com/S/BNTX\">BioNTech&#39;s </a> COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.</p><p>Coming in at No. 2 on the list with predicted sales of ~$20B is <a href=\"https://laohu8.com/S/ABBV\">AbbVie&#39;s </a> TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.</p><p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> products are tied for No. 3. The first is <a href=\"https://laohu8.com/S/MRNA\">Moderna&#39;s </a> COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.</p><p>Also in third place with $19.5B in projected sales is <a href=\"https://laohu8.com/S/MRK\">Merck&#39;s </a> PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_Vantage2022drugsales_thumb1.png\" tg-width=\"1172\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Two <a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb </a> drugs come in the fifth and sixth spots. They are <a href=\"https://laohu8.com/S/apixaban\">Eliquis </a> at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.</p><p>A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.</p><p>Coming in at Nos. 7, 8, and 10 respectively are Johnson &amp; Johnson&#39;s (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences&#39; </a> Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>/<a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a>Dupixent (dupilimuab) (~$7.5B).</p><p>The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson &amp; Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_VantageRxsales_thumb1.png\" tg-width=\"1162\" tg-height=\"614\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&amp;J at around ~$54B.</p><p>In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer&#39;s disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.</p><p>While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&amp;J.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","NVS":"诺华","BK4551":"寇图资本持仓","LLY":"礼来","BK4504":"桥水持仓","SNY":"赛诺菲安万特","BK4548":"巴美列捷福持仓","MRNA":"Moderna, Inc.","BMY":"施贵宝","PFE":"辉瑞","BK4516":"特朗普概念","ABBV":"艾伯维公司","GILD":"吉利德科学","BK4532":"文艺复兴科技持仓","BNTX":"BioNTech SE","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","REGN":"再生元制药公司","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRK":"默沙东","BK4568":"美国抗疫概念"},"source_url":"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207441801","content_text":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.Financial analytics firm Evaluate Vantage projects that Pfizer /BioNTech's  COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.Coming in at No. 2 on the list with predicted sales of ~$20B is AbbVie's  TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.Two products are tied for No. 3. The first is Moderna's  COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.Also in third place with $19.5B in projected sales is Merck's  PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.Two Bristol-Myers Squibb  drugs come in the fifth and sixth spots. They are Eliquis  at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.Coming in at Nos. 7, 8, and 10 respectively are Johnson & Johnson's (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); Gilead Sciences'  Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and Sanofi/Regeneron PharmaceuticalsDupixent (dupilimuab) (~$7.5B).The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson & Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&J at around ~$54B.In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer's disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&J.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093154036,"gmtCreate":1643579845396,"gmtModify":1676533831693,"author":{"id":"3581539047362830","authorId":"3581539047362830","name":"Sunny0809","avatar":"https://static.tigerbbs.com/3ffb7aab0292fd1f17dfb9f99bc5eb03","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093154036","repostId":2207441801,"repostType":4,"repost":{"id":"2207441801","pubTimestamp":1643514032,"share":"https://www.laohu8.com/m/news/2207441801?lang=&edition=full","pubTime":"2022-01-30 11:40","market":"us","language":"en","title":"Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers","url":"https://stock-news.laohu8.com/highlight/detail?id=2207441801","media":"seekingalpha","summary":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with weal","content":"<html><head></head><body><p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn&#39;t come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.</p><p>Financial analytics firm Evaluate Vantage projects that <a href=\"https://laohu8.com/S/PFE\">Pfizer </a>/<a href=\"https://laohu8.com/S/BNTX\">BioNTech&#39;s </a> COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.</p><p>Coming in at No. 2 on the list with predicted sales of ~$20B is <a href=\"https://laohu8.com/S/ABBV\">AbbVie&#39;s </a> TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.</p><p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> products are tied for No. 3. The first is <a href=\"https://laohu8.com/S/MRNA\">Moderna&#39;s </a> COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.</p><p>Also in third place with $19.5B in projected sales is <a href=\"https://laohu8.com/S/MRK\">Merck&#39;s </a> PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_Vantage2022drugsales_thumb1.png\" tg-width=\"1172\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Two <a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb </a> drugs come in the fifth and sixth spots. They are <a href=\"https://laohu8.com/S/apixaban\">Eliquis </a> at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.</p><p>A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.</p><p>Coming in at Nos. 7, 8, and 10 respectively are Johnson &amp; Johnson&#39;s (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences&#39; </a> Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>/<a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a>Dupixent (dupilimuab) (~$7.5B).</p><p>The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson &amp; Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_VantageRxsales_thumb1.png\" tg-width=\"1162\" tg-height=\"614\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&amp;J at around ~$54B.</p><p>In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer&#39;s disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.</p><p>While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&amp;J.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","NVS":"诺华","BK4551":"寇图资本持仓","LLY":"礼来","BK4504":"桥水持仓","SNY":"赛诺菲安万特","BK4548":"巴美列捷福持仓","MRNA":"Moderna, Inc.","BMY":"施贵宝","PFE":"辉瑞","BK4516":"特朗普概念","ABBV":"艾伯维公司","GILD":"吉利德科学","BK4532":"文艺复兴科技持仓","BNTX":"BioNTech SE","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","REGN":"再生元制药公司","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRK":"默沙东","BK4568":"美国抗疫概念"},"source_url":"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207441801","content_text":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.Financial analytics firm Evaluate Vantage projects that Pfizer /BioNTech's  COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.Coming in at No. 2 on the list with predicted sales of ~$20B is AbbVie's  TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.Two products are tied for No. 3. The first is Moderna's  COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.Also in third place with $19.5B in projected sales is Merck's  PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.Two Bristol-Myers Squibb  drugs come in the fifth and sixth spots. They are Eliquis  at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.Coming in at Nos. 7, 8, and 10 respectively are Johnson & Johnson's (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); Gilead Sciences'  Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and Sanofi/Regeneron PharmaceuticalsDupixent (dupilimuab) (~$7.5B).The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson & Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&J at around ~$54B.In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer's disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&J.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093155807,"gmtCreate":1643579571466,"gmtModify":1676533831669,"author":{"id":"3574044380631135","authorId":"3574044380631135","name":"Alkid","avatar":"https://static.tigerbbs.com/d584ca72b32575d58fab92034b2973bc","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093155807","repostId":2207441801,"repostType":4,"repost":{"id":"2207441801","pubTimestamp":1643514032,"share":"https://www.laohu8.com/m/news/2207441801?lang=&edition=full","pubTime":"2022-01-30 11:40","market":"us","language":"en","title":"Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers","url":"https://stock-news.laohu8.com/highlight/detail?id=2207441801","media":"seekingalpha","summary":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with weal","content":"<html><head></head><body><p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn&#39;t come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.</p><p>Financial analytics firm Evaluate Vantage projects that <a href=\"https://laohu8.com/S/PFE\">Pfizer </a>/<a href=\"https://laohu8.com/S/BNTX\">BioNTech&#39;s </a> COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.</p><p>Coming in at No. 2 on the list with predicted sales of ~$20B is <a href=\"https://laohu8.com/S/ABBV\">AbbVie&#39;s </a> TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.</p><p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> products are tied for No. 3. The first is <a href=\"https://laohu8.com/S/MRNA\">Moderna&#39;s </a> COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.</p><p>Also in third place with $19.5B in projected sales is <a href=\"https://laohu8.com/S/MRK\">Merck&#39;s </a> PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_Vantage2022drugsales_thumb1.png\" tg-width=\"1172\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Two <a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb </a> drugs come in the fifth and sixth spots. They are <a href=\"https://laohu8.com/S/apixaban\">Eliquis </a> at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.</p><p>A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.</p><p>Coming in at Nos. 7, 8, and 10 respectively are Johnson &amp; Johnson&#39;s (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences&#39; </a> Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>/<a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a>Dupixent (dupilimuab) (~$7.5B).</p><p>The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson &amp; Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_VantageRxsales_thumb1.png\" tg-width=\"1162\" tg-height=\"614\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&amp;J at around ~$54B.</p><p>In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer&#39;s disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.</p><p>While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&amp;J.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","NVS":"诺华","BK4551":"寇图资本持仓","LLY":"礼来","BK4504":"桥水持仓","SNY":"赛诺菲安万特","BK4548":"巴美列捷福持仓","MRNA":"Moderna, Inc.","BMY":"施贵宝","PFE":"辉瑞","BK4516":"特朗普概念","ABBV":"艾伯维公司","GILD":"吉利德科学","BK4532":"文艺复兴科技持仓","BNTX":"BioNTech SE","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","REGN":"再生元制药公司","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRK":"默沙东","BK4568":"美国抗疫概念"},"source_url":"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207441801","content_text":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.Financial analytics firm Evaluate Vantage projects that Pfizer /BioNTech's  COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.Coming in at No. 2 on the list with predicted sales of ~$20B is AbbVie's  TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.Two products are tied for No. 3. The first is Moderna's  COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.Also in third place with $19.5B in projected sales is Merck's  PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.Two Bristol-Myers Squibb  drugs come in the fifth and sixth spots. They are Eliquis  at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.Coming in at Nos. 7, 8, and 10 respectively are Johnson & Johnson's (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); Gilead Sciences'  Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and Sanofi/Regeneron PharmaceuticalsDupixent (dupilimuab) (~$7.5B).The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson & Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&J at around ~$54B.In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer's disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&J.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093156190,"gmtCreate":1643578229620,"gmtModify":1676533831622,"author":{"id":"3548659340886358","authorId":"3548659340886358","name":"老木不朽","avatar":"https://static.tigerbbs.com/5b7c249f8702df4b6d4a8a6346ce6b5d","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093156190","repostId":2207441801,"repostType":4,"repost":{"id":"2207441801","pubTimestamp":1643514032,"share":"https://www.laohu8.com/m/news/2207441801?lang=&edition=full","pubTime":"2022-01-30 11:40","market":"us","language":"en","title":"Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers","url":"https://stock-news.laohu8.com/highlight/detail?id=2207441801","media":"seekingalpha","summary":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with weal","content":"<html><head></head><body><p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn&#39;t come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.</p><p>Financial analytics firm Evaluate Vantage projects that <a href=\"https://laohu8.com/S/PFE\">Pfizer </a>/<a href=\"https://laohu8.com/S/BNTX\">BioNTech&#39;s </a> COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.</p><p>Coming in at No. 2 on the list with predicted sales of ~$20B is <a href=\"https://laohu8.com/S/ABBV\">AbbVie&#39;s </a> TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.</p><p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> products are tied for No. 3. The first is <a href=\"https://laohu8.com/S/MRNA\">Moderna&#39;s </a> COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.</p><p>Also in third place with $19.5B in projected sales is <a href=\"https://laohu8.com/S/MRK\">Merck&#39;s </a> PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_Vantage2022drugsales_thumb1.png\" tg-width=\"1172\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Two <a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb </a> drugs come in the fifth and sixth spots. They are <a href=\"https://laohu8.com/S/apixaban\">Eliquis </a> at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.</p><p>A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.</p><p>Coming in at Nos. 7, 8, and 10 respectively are Johnson &amp; Johnson&#39;s (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences&#39; </a> Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>/<a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a>Dupixent (dupilimuab) (~$7.5B).</p><p>The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson &amp; Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_VantageRxsales_thumb1.png\" tg-width=\"1162\" tg-height=\"614\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&amp;J at around ~$54B.</p><p>In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer&#39;s disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.</p><p>While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&amp;J.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","NVS":"诺华","BK4551":"寇图资本持仓","LLY":"礼来","BK4504":"桥水持仓","SNY":"赛诺菲安万特","BK4548":"巴美列捷福持仓","MRNA":"Moderna, Inc.","BMY":"施贵宝","PFE":"辉瑞","BK4516":"特朗普概念","ABBV":"艾伯维公司","GILD":"吉利德科学","BK4532":"文艺复兴科技持仓","BNTX":"BioNTech SE","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","REGN":"再生元制药公司","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRK":"默沙东","BK4568":"美国抗疫概念"},"source_url":"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207441801","content_text":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.Financial analytics firm Evaluate Vantage projects that Pfizer /BioNTech's  COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.Coming in at No. 2 on the list with predicted sales of ~$20B is AbbVie's  TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.Two products are tied for No. 3. The first is Moderna's  COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.Also in third place with $19.5B in projected sales is Merck's  PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.Two Bristol-Myers Squibb  drugs come in the fifth and sixth spots. They are Eliquis  at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.Coming in at Nos. 7, 8, and 10 respectively are Johnson & Johnson's (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); Gilead Sciences'  Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and Sanofi/Regeneron PharmaceuticalsDupixent (dupilimuab) (~$7.5B).The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson & Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&J at around ~$54B.In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer's disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&J.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093151970,"gmtCreate":1643576733600,"gmtModify":1676533831581,"author":{"id":"3582359360248748","authorId":"3582359360248748","name":"ML808","avatar":"https://static.tigerbbs.com/f601c68849ffbac8b7679f40f1471368","vip":1,"hat":"https://static.tigerbbs.com/7b75ce0c34afff716602792a5d0929dd","crmLevel":4,"crmLevelSwitch":0},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093151970","repostId":2207441801,"repostType":4,"repost":{"id":"2207441801","pubTimestamp":1643514032,"share":"https://www.laohu8.com/m/news/2207441801?lang=&edition=full","pubTime":"2022-01-30 11:40","market":"us","language":"en","title":"Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers","url":"https://stock-news.laohu8.com/highlight/detail?id=2207441801","media":"seekingalpha","summary":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with weal","content":"<html><head></head><body><p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn&#39;t come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.</p><p>Financial analytics firm Evaluate Vantage projects that <a href=\"https://laohu8.com/S/PFE\">Pfizer </a>/<a href=\"https://laohu8.com/S/BNTX\">BioNTech&#39;s </a> COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.</p><p>Coming in at No. 2 on the list with predicted sales of ~$20B is <a href=\"https://laohu8.com/S/ABBV\">AbbVie&#39;s </a> TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.</p><p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> products are tied for No. 3. The first is <a href=\"https://laohu8.com/S/MRNA\">Moderna&#39;s </a> COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.</p><p>Also in third place with $19.5B in projected sales is <a href=\"https://laohu8.com/S/MRK\">Merck&#39;s </a> PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_Vantage2022drugsales_thumb1.png\" tg-width=\"1172\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Two <a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb </a> drugs come in the fifth and sixth spots. They are <a href=\"https://laohu8.com/S/apixaban\">Eliquis </a> at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.</p><p>A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.</p><p>Coming in at Nos. 7, 8, and 10 respectively are Johnson &amp; Johnson&#39;s (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences&#39; </a> Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>/<a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a>Dupixent (dupilimuab) (~$7.5B).</p><p>The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson &amp; Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_VantageRxsales_thumb1.png\" tg-width=\"1162\" tg-height=\"614\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&amp;J at around ~$54B.</p><p>In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer&#39;s disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.</p><p>While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&amp;J.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","NVS":"诺华","BK4551":"寇图资本持仓","LLY":"礼来","BK4504":"桥水持仓","SNY":"赛诺菲安万特","BK4548":"巴美列捷福持仓","MRNA":"Moderna, Inc.","BMY":"施贵宝","PFE":"辉瑞","BK4516":"特朗普概念","ABBV":"艾伯维公司","GILD":"吉利德科学","BK4532":"文艺复兴科技持仓","BNTX":"BioNTech SE","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","REGN":"再生元制药公司","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRK":"默沙东","BK4568":"美国抗疫概念"},"source_url":"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207441801","content_text":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.Financial analytics firm Evaluate Vantage projects that Pfizer /BioNTech's  COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.Coming in at No. 2 on the list with predicted sales of ~$20B is AbbVie's  TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.Two products are tied for No. 3. The first is Moderna's  COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.Also in third place with $19.5B in projected sales is Merck's  PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.Two Bristol-Myers Squibb  drugs come in the fifth and sixth spots. They are Eliquis  at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.Coming in at Nos. 7, 8, and 10 respectively are Johnson & Johnson's (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); Gilead Sciences'  Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and Sanofi/Regeneron PharmaceuticalsDupixent (dupilimuab) (~$7.5B).The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson & Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&J at around ~$54B.In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer's disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&J.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093150782,"gmtCreate":1643572343547,"gmtModify":1676533831512,"author":{"id":"3572867658695568","authorId":"3572867658695568","name":"Simplewind","avatar":"https://static.tigerbbs.com/5cec05c297ad50a1f25f590f1266e874","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Pls like. Thanks","listText":"Pls like. Thanks","text":"Pls like. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093150782","repostId":2207441801,"repostType":4,"repost":{"id":"2207441801","pubTimestamp":1643514032,"share":"https://www.laohu8.com/m/news/2207441801?lang=&edition=full","pubTime":"2022-01-30 11:40","market":"us","language":"en","title":"Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers","url":"https://stock-news.laohu8.com/highlight/detail?id=2207441801","media":"seekingalpha","summary":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with weal","content":"<html><head></head><body><p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn&#39;t come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.</p><p>Financial analytics firm Evaluate Vantage projects that <a href=\"https://laohu8.com/S/PFE\">Pfizer </a>/<a href=\"https://laohu8.com/S/BNTX\">BioNTech&#39;s </a> COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.</p><p>Coming in at No. 2 on the list with predicted sales of ~$20B is <a href=\"https://laohu8.com/S/ABBV\">AbbVie&#39;s </a> TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.</p><p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> products are tied for No. 3. The first is <a href=\"https://laohu8.com/S/MRNA\">Moderna&#39;s </a> COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.</p><p>Also in third place with $19.5B in projected sales is <a href=\"https://laohu8.com/S/MRK\">Merck&#39;s </a> PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_Vantage2022drugsales_thumb1.png\" tg-width=\"1172\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Two <a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb </a> drugs come in the fifth and sixth spots. They are <a href=\"https://laohu8.com/S/apixaban\">Eliquis </a> at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.</p><p>A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.</p><p>Coming in at Nos. 7, 8, and 10 respectively are Johnson &amp; Johnson&#39;s (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences&#39; </a> Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>/<a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a>Dupixent (dupilimuab) (~$7.5B).</p><p>The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson &amp; Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_VantageRxsales_thumb1.png\" tg-width=\"1162\" tg-height=\"614\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&amp;J at around ~$54B.</p><p>In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer&#39;s disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.</p><p>While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&amp;J.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","NVS":"诺华","BK4551":"寇图资本持仓","LLY":"礼来","BK4504":"桥水持仓","SNY":"赛诺菲安万特","BK4548":"巴美列捷福持仓","MRNA":"Moderna, Inc.","BMY":"施贵宝","PFE":"辉瑞","BK4516":"特朗普概念","ABBV":"艾伯维公司","GILD":"吉利德科学","BK4532":"文艺复兴科技持仓","BNTX":"BioNTech SE","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","REGN":"再生元制药公司","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRK":"默沙东","BK4568":"美国抗疫概念"},"source_url":"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207441801","content_text":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.Financial analytics firm Evaluate Vantage projects that Pfizer /BioNTech's  COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.Coming in at No. 2 on the list with predicted sales of ~$20B is AbbVie's  TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.Two products are tied for No. 3. The first is Moderna's  COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.Also in third place with $19.5B in projected sales is Merck's  PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.Two Bristol-Myers Squibb  drugs come in the fifth and sixth spots. They are Eliquis  at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.Coming in at Nos. 7, 8, and 10 respectively are Johnson & Johnson's (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); Gilead Sciences'  Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and Sanofi/Regeneron PharmaceuticalsDupixent (dupilimuab) (~$7.5B).The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson & Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&J at around ~$54B.In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer's disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&J.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093127432,"gmtCreate":1643569638208,"gmtModify":1676533831495,"author":{"id":"3562654257787729","authorId":"3562654257787729","name":"whyskysoshy","avatar":"https://static.tigerbbs.com/ee5578884e55299564c78e63e978d3ca","vip":1,"hat":"https://static.tigerbbs.com/3b7820dfed76481d8dc4de6ac5a7a136","crmLevel":9,"crmLevelSwitch":1},"htmlText":"🤙","listText":"🤙","text":"🤙","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093127432","repostId":2207441801,"repostType":4,"repost":{"id":"2207441801","pubTimestamp":1643514032,"share":"https://www.laohu8.com/m/news/2207441801?lang=&edition=full","pubTime":"2022-01-30 11:40","market":"us","language":"en","title":"Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers","url":"https://stock-news.laohu8.com/highlight/detail?id=2207441801","media":"seekingalpha","summary":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with weal","content":"<html><head></head><body><p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn&#39;t come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.</p><p>Financial analytics firm Evaluate Vantage projects that <a href=\"https://laohu8.com/S/PFE\">Pfizer </a>/<a href=\"https://laohu8.com/S/BNTX\">BioNTech&#39;s </a> COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.</p><p>Coming in at No. 2 on the list with predicted sales of ~$20B is <a href=\"https://laohu8.com/S/ABBV\">AbbVie&#39;s </a> TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.</p><p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> products are tied for No. 3. The first is <a href=\"https://laohu8.com/S/MRNA\">Moderna&#39;s </a> COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.</p><p>Also in third place with $19.5B in projected sales is <a href=\"https://laohu8.com/S/MRK\">Merck&#39;s </a> PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_Vantage2022drugsales_thumb1.png\" tg-width=\"1172\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Two <a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb </a> drugs come in the fifth and sixth spots. They are <a href=\"https://laohu8.com/S/apixaban\">Eliquis </a> at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.</p><p>A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.</p><p>Coming in at Nos. 7, 8, and 10 respectively are Johnson &amp; Johnson&#39;s (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences&#39; </a> Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>/<a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a>Dupixent (dupilimuab) (~$7.5B).</p><p>The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson &amp; Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_VantageRxsales_thumb1.png\" tg-width=\"1162\" tg-height=\"614\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&amp;J at around ~$54B.</p><p>In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer&#39;s disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.</p><p>While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&amp;J.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","NVS":"诺华","BK4551":"寇图资本持仓","LLY":"礼来","BK4504":"桥水持仓","SNY":"赛诺菲安万特","BK4548":"巴美列捷福持仓","MRNA":"Moderna, Inc.","BMY":"施贵宝","PFE":"辉瑞","BK4516":"特朗普概念","ABBV":"艾伯维公司","GILD":"吉利德科学","BK4532":"文艺复兴科技持仓","BNTX":"BioNTech SE","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","REGN":"再生元制药公司","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRK":"默沙东","BK4568":"美国抗疫概念"},"source_url":"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207441801","content_text":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.Financial analytics firm Evaluate Vantage projects that Pfizer /BioNTech's  COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.Coming in at No. 2 on the list with predicted sales of ~$20B is AbbVie's  TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.Two products are tied for No. 3. The first is Moderna's  COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.Also in third place with $19.5B in projected sales is Merck's  PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.Two Bristol-Myers Squibb  drugs come in the fifth and sixth spots. They are Eliquis  at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.Coming in at Nos. 7, 8, and 10 respectively are Johnson & Johnson's (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); Gilead Sciences'  Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and Sanofi/Regeneron PharmaceuticalsDupixent (dupilimuab) (~$7.5B).The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson & Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&J at around ~$54B.In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer's disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&J.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093128192,"gmtCreate":1643562122648,"gmtModify":1676533831386,"author":{"id":"3581743394055717","authorId":"3581743394055717","name":"Zero_onezero","avatar":"https://static.tigerbbs.com/f93660d80ec28ae67a094cb5c0c44350","vip":1,"crmLevel":2,"crmLevelSwitch":1},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093128192","repostId":2207441801,"repostType":4,"repost":{"id":"2207441801","pubTimestamp":1643514032,"share":"https://www.laohu8.com/m/news/2207441801?lang=&edition=full","pubTime":"2022-01-30 11:40","market":"us","language":"en","title":"Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers","url":"https://stock-news.laohu8.com/highlight/detail?id=2207441801","media":"seekingalpha","summary":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with weal","content":"<html><head></head><body><p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn&#39;t come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.</p><p>Financial analytics firm Evaluate Vantage projects that <a href=\"https://laohu8.com/S/PFE\">Pfizer </a>/<a href=\"https://laohu8.com/S/BNTX\">BioNTech&#39;s </a> COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.</p><p>Coming in at No. 2 on the list with predicted sales of ~$20B is <a href=\"https://laohu8.com/S/ABBV\">AbbVie&#39;s </a> TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.</p><p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> products are tied for No. 3. The first is <a href=\"https://laohu8.com/S/MRNA\">Moderna&#39;s </a> COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.</p><p>Also in third place with $19.5B in projected sales is <a href=\"https://laohu8.com/S/MRK\">Merck&#39;s </a> PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_Vantage2022drugsales_thumb1.png\" tg-width=\"1172\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Two <a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb </a> drugs come in the fifth and sixth spots. They are <a href=\"https://laohu8.com/S/apixaban\">Eliquis </a> at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.</p><p>A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.</p><p>Coming in at Nos. 7, 8, and 10 respectively are Johnson &amp; Johnson&#39;s (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences&#39; </a> Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>/<a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a>Dupixent (dupilimuab) (~$7.5B).</p><p>The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson &amp; Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_VantageRxsales_thumb1.png\" tg-width=\"1162\" tg-height=\"614\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&amp;J at around ~$54B.</p><p>In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer&#39;s disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.</p><p>While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&amp;J.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","NVS":"诺华","BK4551":"寇图资本持仓","LLY":"礼来","BK4504":"桥水持仓","SNY":"赛诺菲安万特","BK4548":"巴美列捷福持仓","MRNA":"Moderna, Inc.","BMY":"施贵宝","PFE":"辉瑞","BK4516":"特朗普概念","ABBV":"艾伯维公司","GILD":"吉利德科学","BK4532":"文艺复兴科技持仓","BNTX":"BioNTech SE","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","REGN":"再生元制药公司","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRK":"默沙东","BK4568":"美国抗疫概念"},"source_url":"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207441801","content_text":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.Financial analytics firm Evaluate Vantage projects that Pfizer /BioNTech's  COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.Coming in at No. 2 on the list with predicted sales of ~$20B is AbbVie's  TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.Two products are tied for No. 3. The first is Moderna's  COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.Also in third place with $19.5B in projected sales is Merck's  PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.Two Bristol-Myers Squibb  drugs come in the fifth and sixth spots. They are Eliquis  at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.Coming in at Nos. 7, 8, and 10 respectively are Johnson & Johnson's (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); Gilead Sciences'  Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and Sanofi/Regeneron PharmaceuticalsDupixent (dupilimuab) (~$7.5B).The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson & Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&J at around ~$54B.In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer's disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&J.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093167795,"gmtCreate":1643559328637,"gmtModify":1676533831267,"author":{"id":"3559194206832147","authorId":"3559194206832147","name":"JoshuaLiew","avatar":"https://static.tigerbbs.com/b503d223679dec0ab7416f6186269f11","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093167795","repostId":2207441801,"repostType":4,"repost":{"id":"2207441801","pubTimestamp":1643514032,"share":"https://www.laohu8.com/m/news/2207441801?lang=&edition=full","pubTime":"2022-01-30 11:40","market":"us","language":"en","title":"Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers","url":"https://stock-news.laohu8.com/highlight/detail?id=2207441801","media":"seekingalpha","summary":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with weal","content":"<html><head></head><body><p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn&#39;t come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.</p><p>Financial analytics firm Evaluate Vantage projects that <a href=\"https://laohu8.com/S/PFE\">Pfizer </a>/<a href=\"https://laohu8.com/S/BNTX\">BioNTech&#39;s </a> COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.</p><p>Coming in at No. 2 on the list with predicted sales of ~$20B is <a href=\"https://laohu8.com/S/ABBV\">AbbVie&#39;s </a> TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.</p><p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> products are tied for No. 3. The first is <a href=\"https://laohu8.com/S/MRNA\">Moderna&#39;s </a> COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.</p><p>Also in third place with $19.5B in projected sales is <a href=\"https://laohu8.com/S/MRK\">Merck&#39;s </a> PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_Vantage2022drugsales_thumb1.png\" tg-width=\"1172\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Two <a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb </a> drugs come in the fifth and sixth spots. They are <a href=\"https://laohu8.com/S/apixaban\">Eliquis </a> at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.</p><p>A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.</p><p>Coming in at Nos. 7, 8, and 10 respectively are Johnson &amp; Johnson&#39;s (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences&#39; </a> Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>/<a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a>Dupixent (dupilimuab) (~$7.5B).</p><p>The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson &amp; Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_VantageRxsales_thumb1.png\" tg-width=\"1162\" tg-height=\"614\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&amp;J at around ~$54B.</p><p>In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer&#39;s disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.</p><p>While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&amp;J.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","NVS":"诺华","BK4551":"寇图资本持仓","LLY":"礼来","BK4504":"桥水持仓","SNY":"赛诺菲安万特","BK4548":"巴美列捷福持仓","MRNA":"Moderna, Inc.","BMY":"施贵宝","PFE":"辉瑞","BK4516":"特朗普概念","ABBV":"艾伯维公司","GILD":"吉利德科学","BK4532":"文艺复兴科技持仓","BNTX":"BioNTech SE","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","REGN":"再生元制药公司","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRK":"默沙东","BK4568":"美国抗疫概念"},"source_url":"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207441801","content_text":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.Financial analytics firm Evaluate Vantage projects that Pfizer /BioNTech's  COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.Coming in at No. 2 on the list with predicted sales of ~$20B is AbbVie's  TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.Two products are tied for No. 3. The first is Moderna's  COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.Also in third place with $19.5B in projected sales is Merck's  PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.Two Bristol-Myers Squibb  drugs come in the fifth and sixth spots. They are Eliquis  at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.Coming in at Nos. 7, 8, and 10 respectively are Johnson & Johnson's (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); Gilead Sciences'  Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and Sanofi/Regeneron PharmaceuticalsDupixent (dupilimuab) (~$7.5B).The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson & Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&J at around ~$54B.In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer's disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&J.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093165025,"gmtCreate":1643558714883,"gmtModify":1676533831125,"author":{"id":"3565930395680990","authorId":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"🤑","listText":"🤑","text":"🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093165025","repostId":2207441801,"repostType":4,"repost":{"id":"2207441801","pubTimestamp":1643514032,"share":"https://www.laohu8.com/m/news/2207441801?lang=&edition=full","pubTime":"2022-01-30 11:40","market":"us","language":"en","title":"Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers","url":"https://stock-news.laohu8.com/highlight/detail?id=2207441801","media":"seekingalpha","summary":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with weal","content":"<html><head></head><body><p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn&#39;t come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.</p><p>Financial analytics firm Evaluate Vantage projects that <a href=\"https://laohu8.com/S/PFE\">Pfizer </a>/<a href=\"https://laohu8.com/S/BNTX\">BioNTech&#39;s </a> COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.</p><p>Coming in at No. 2 on the list with predicted sales of ~$20B is <a href=\"https://laohu8.com/S/ABBV\">AbbVie&#39;s </a> TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.</p><p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> products are tied for No. 3. The first is <a href=\"https://laohu8.com/S/MRNA\">Moderna&#39;s </a> COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.</p><p>Also in third place with $19.5B in projected sales is <a href=\"https://laohu8.com/S/MRK\">Merck&#39;s </a> PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_Vantage2022drugsales_thumb1.png\" tg-width=\"1172\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Two <a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb </a> drugs come in the fifth and sixth spots. They are <a href=\"https://laohu8.com/S/apixaban\">Eliquis </a> at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.</p><p>A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.</p><p>Coming in at Nos. 7, 8, and 10 respectively are Johnson &amp; Johnson&#39;s (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences&#39; </a> Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>/<a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a>Dupixent (dupilimuab) (~$7.5B).</p><p>The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson &amp; Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.</p><p><img src=\"https://static.seekingalpha.com/uploads/2022/1/28/saupload_VantageRxsales_thumb1.png\" tg-width=\"1162\" tg-height=\"614\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&amp;J at around ~$54B.</p><p>In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer&#39;s disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.</p><p>While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&amp;J.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccines to Dominate Pharma Sales This Year, but Bristol Could Have Most Best-Sellers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","NVS":"诺华","BK4551":"寇图资本持仓","LLY":"礼来","BK4504":"桥水持仓","SNY":"赛诺菲安万特","BK4548":"巴美列捷福持仓","MRNA":"Moderna, Inc.","BMY":"施贵宝","PFE":"辉瑞","BK4516":"特朗普概念","ABBV":"艾伯维公司","GILD":"吉利德科学","BK4532":"文艺复兴科技持仓","BNTX":"BioNTech SE","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","REGN":"再生元制药公司","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","MRK":"默沙东","BK4568":"美国抗疫概念"},"source_url":"https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207441801","content_text":"Given the continued strong demand for COVID-19 vaccines, especially from ongoing contracts with wealthier countries, it doesn't come as a surprise that two of the three top-selling pharmaceutical products this year are expected to be vaccines.Financial analytics firm Evaluate Vantage projects that Pfizer /BioNTech's  COVID vaccine known as Comirnaty will be the top selling product this year with sales ~$29B.Coming in at No. 2 on the list with predicted sales of ~$20B is AbbVie's  TNF-alpha blocker Humira (adalimumab). Until COVID vaccines became available in late 2020, Humira had dominated the top spot as the top-selling drug in the U.S. for many years.Two products are tied for No. 3. The first is Moderna's  COVID vaccine called Spikevax that is expected to earn $19.5B for the company. Earlier this month, CEO Stephane Bancel said Moderna signed $18.5B worth of advance purchase agreements for its COVID vaccine this year.Also in third place with $19.5B in projected sales is Merck's  PD-1 inhibitor used in a variety of cancer indications Keytruda (pembrolizumab). Recent research indicated that the monoclonal antibody may also be effective as an HIV therapy.Two Bristol-Myers Squibb  drugs come in the fifth and sixth spots. They are Eliquis  at ~$12B and Revlimid (lenalidomide) at just over $11B. Bristol shares Eliquis revenues with partner Pfizer. Bristol could see generic competition for Revlimid next year.A third Bristol drug made the top 10 list with Opdivo (nivolumab) at No. 9 with ~$9B in projected sales. In November, the company posted encouraging data from a late-stage Opdivo trial in non-small cell lung cancer.Coming in at Nos. 7, 8, and 10 respectively are Johnson & Johnson's (NYSE:JNJ) Stelara (ustekinumab) ($10.1B); Gilead Sciences'  Biktarvy (bictegravir/emtricitabine/tenofovir) (just under $10B); and Sanofi/Regeneron PharmaceuticalsDupixent (dupilimuab) (~$7.5B).The Evaluate Vantage report also estimates the biggest pharmaceutical companies for 2022 based on prescription drug sales. The top five in order are Pfizer, AbbVie, Johnson & Johnson, Novartis (NYSE:NVS), and Bristol-Myers Squibb.Pfizer is projected to have ~$67B in revenue followed by Abbvie with ~$58B, and J&J at around ~$54B.In another statistic, Evaluate Vantage also predicts that Eli Lilly (NYSE:LLY) will have the two biggest launches of the year: donanemab for Alzheimer's disease and tirzepatide for type 2 diabetes. The firm predicts peak 2026 sales of the former at $6B and of the latter at $4.9B.While the future for COVID-19 vaccines beyond 2022 is uncertain, a potential decline in sales is likely to have a much bigger impact on smaller companies, such as Moderna, than bigger ones such as Pfizer and J&J.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":767,"commentSize":50,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}